Table I.
Summary of patient characteristics with intracranial extranodal marginal zone B-cell lymphomas.
| First author/s, year | Case | Age | Sex | Location | Symptoms | Treatment | Remission/outcome | Immunohistochemistry | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|
| Rottnek et al, 2004 | 1 | 47 | M | Left tentorial | Seizure, visual field defects and memory loss | Subtotal excision and radiation | NED at 8 months | CD20+, CD79a+, CD43+ and kappa LCR | (9) |
| Kambham et al, 1998 | 2 | 39 | F | Left CP angle (dura) | Hearing loss and facial pain/weakness | Subtotal excision | AWD after 4 years | CD20+, CD79a+, CD21+ germinal centers and kappa LCR | (17) |
| 3 | 62 | F | Left parietal-occipital area | Headaches | Radiation | AWD after 6 months | CD20+ and CD79a+ | ||
| Kumar et al, 1997 | 4 | 40 | F | Right cavernous sinus | Numbness and visual field defects | Radiation | NED at 63 months | CD20+, CD3+ reactive T cells and lambda LCR | (10) |
| 5 | 62 | F | Biparietal dural | Seizures | Fludarabine | NED at 22 months | CD20+, CD3+ reactive T cells and lambda LCR | ||
| 6 | 52 | F | Left frontal dural | Seizures and numbness | Radiation/chemotherapy | NED at 9 months | CD20+, CD3+ reactive T cells and kappa LCR | ||
| 7 | 43 | F | Left tentorial | Dizziness, headaches, blurred vision and numbness | Radiation | NED at 7 months | CD20+, CD3+ reactive T cells, CD43+ and lambda LCR | ||
| 8 | 57 | F | Left anterior falx cerebri | Seizures | Radiation | NED at 14 months | CD20+, CD3+ reactive T cells, CD43+ and CD23− | ||
| Itoh et al, 2001 | 9 | 28 | F | CP angle | Tinnitus, nausea, headache and bilateral papilledema | Excision | NED at 2 years | CD20+, CD10+ (follicular center cells), BCL2+ in some follicular centers, CD43+ and CD3+ (50% cells) | (18) |
| Goetz et al, 2002 | 10 | 64 | F | Right frontoparietal dura | Left hemiparesis and headache | Excision and radiation | NED at 3 months | IgD+/CD20+ small lymphocytes, IgD−/CD20+ lymphoplasmacytoid cells, CD20−/CD138+ plasma cells and kappa LCR | (13) |
| Ferguson et al, 2010 | 11 | 29 | F | Right frontal dural | Exophthalmos and visual loss | Decompression of the optic nerve, subtotal resection and 30 Gy radiation | NED at 3 years | CD20+, BCL-6−, kappa LCR and CD5− | (14) |
| Jesionek-Kupnicka et al, 2013 | 12 | 60 | F | Left parietooccipital dural | Headache, periodic cramp of the right face and numbness of the | Excision and radiotherapy (WS3D 6MV photons) | NED | CD20+, CD79a+, BCL-2+ (reactive follicles with germinal centers), CD3−, CD5−, CD23−, CD10−, BCL-6−, Cyclin D1−, Ki-67+ (10%), | (4) |
| Kamoshima et al, 2011 | 13 | 55 | F | Left frontal dural | Seizures | Subtotal excision and 40 Gy radiation | NED at 36 months | CD20+, CD5−, CD23−, CD10−, Cyclin D1−, CD3+ (some lymphocytes) | (8) |
| Shaia et al, 2010 | 14 | 61 | F | Dura of the right posterior fossa | Nausea, vomiting and pain over the top of scalp | Excision and 30 Gy radiation | NED at 6 months | CD20+, CD79a+, CD5−, CD10−, CD23−, CD43− and kappa LCR | (19) |
| Tu et al, 2005 | 15 | 49 | M | Frontal | Seizures | Chemotherapy (MTX and fludarabine) | NED at 7.6 years | Not available | (20) |
| 16 | 48 | F | Dura, tentorium and falx | Headache and ear pain | Chemotherapy (MTX and leucovorin) and radiation | NED at 20 months | Not available | ||
| Lehman et al, 2002 | 17 | 63 | F | Supratentorial and infratentorial dural | Seizure | Excision and 36 Gy radiation | NED | CD20+, CD45+, CD3+ (small population) and CD138+ (small population) | (21) |
| Venkataraman et al, 2011 | 18 | 62 | F | Bilateral parietal | Unknown | Fludarabine | NED at 22 months | Not available | (15) |
| Villeneuve et al, 2018 | 19 | 60 | F | Petrous temporal bone | Vertigo and unilateral right mixed hearing loss | Chemotherapy (rituximab and bendamustine) | NED at 2years | CD20+, CD23+, CD5−, CD10−, BCL-1− and BCL-2+ | (22) |
| Park et al, 2008 | 20 | 18 | M | Left basal ganglia | Right-sided central facial nerve palsy, right-sided weakness, dizziness and dysarthria | Radiation | NED at 22 months | CD20+, CD79a+, CD3−, CD5−, CD10−, BCL-6−, CD23−, MUM1-, ALK-1−, Cyclin D1−, and negative for kappa and lambda LCR | (12) |
| Kelley et al, 2005 | 21 | 53 | M | Right lateral ventricle | Headache and seizure | Excision and chemotherapy (liposomal cytarabine) | NED at 14 months | CD19+, CD20+, CD45+, CD5−, CD10− | (23) |
| Jazy et al, 1980 | 22 | 59 | M | Right temporal | Seizures, visual and hearing impairment | Radiation | NED at 16 months | Not available | (24) |
| Miranda et al, 1996 | 24 | 51 | F | Right frontal | Major motor seizure | Excision and radiation | NED at 14 months | CD19+, CD20+ and CD22+ | (25) |
| Naberhaus et al, 1996 | 25 | 48 | F | Right temporo-parietal | Headaches | Radiation | NED at 36 months | CD20+ | (26) |
| King et al, 1998 | 26 | 60 | F | Cerebellar vermis and right fronto-parietooccipital | Seizures and memory loss | Biopsy and chemotherapy | Died 3 months later due to pneumonia | CD45RB+, CD20+, Cyclin D1 | (27) |
| Hodgson et al, 1999 | 27 | 57 | F | Right sphenoid wing | Headache and mild | Excision photophobia | NED at 6 months | CD20+, kappa LCR, BCL-2+ | (28) |
| Freudenstein et al, 2000 | 28 | 50 | F | Parafalcine and bilateral convexity dura | Headache and seizures | Systemic and intrathecal chemotherapy (MTX) | NED at 36 months | CD20+, LCA+, Vimentin+, CD3−, IgG light chain− and IgG heavy chain− | (29) |
| Neidert et al, 2015 | 29 | 44 | M | Right fronto-parietal dural | Involuntary muscle movements on the left-side of his body | Excision and 36 Gy radiation | NED at 2 years | CD20+, CD45+, BCL-2+, CD79a+, EMA−, CD34−, TDT−, CD99−, Ki-67+ (30%), CD3+, CD5+, CD10+, CD23+ (small population) | (30) |
| Pavlou et al, 2006 | 30 | 73 | F | Left fronto-parietal | Right arm weakness, partial seizures and dysphasia | Excision and chemotherapy (methylpred-nisolone, cytosine and methotrexate, chlorambucil) | Unknown | CD20+, CD79+, BCL-2+, CD10−, BCL-1−, CD5−, MIB-1+ (10%) | (31) |
| Present study | 31 | 59 | F | Left temporal lobe | Dizziness and bilateral leg weakness | Excision | AWD after 6 years | CD20+; CD79a+, CD21+, CD23 follicle+; Ki-67+ 5%; BCL-2+; CD10+ 10%; CD3+, CD5+ CD43 T-cell+, Cyclin D1−, MPO− and CD68- |
AWD, alive with disease; F, female; LCR, light chain restriction; M, male; MPO, myeloperoxidase; NED, no evidence of disease; CP, cerebellopontine; MTX, methotrexate; LCA, leukocyte common antigen; EMA, epithelial membrane antigen; TDT, terminal deoxynucleotide transferase.